Harvard Apparatus Regenerative Technology Schedules Conference Call and Webcast for Q2 2023 Results Aug 9, 2023 02:54PM
Biostage, Inc. Changes Name to Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) Jul 20, 2023 09:00AM
Biostage Activated Mayo Clinic as The First Site for Clinical Trial in Severe Esophageal Disease Jul 18, 2023 09:00AM
Biostage to Host Investor Call Jun 13, 2023 02:31PM
Biostage Initiated Study Start-up Activities for Clinical Trial in Severe Esophageal Disease May 31, 2023 09:15AM
View Older Stories

Apr 10, 2023 09:30AM Biostage Appoints Ron Packard to Board of Directors
Apr 6, 2023 09:30AM Biostage Announces $6 Million Financing to Advance Clinical Trial
Mar 2, 2023 05:47AM Biostage (BSTG) Announces Chairman and CEO Transition
Mar 1, 2023 09:17PM Biostage Announces Chairman and CEO Transition
Jan 12, 2023 08:30AM Biostage Amends CEO Employment Agreement
Dec 28, 2022 08:30AM Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including Cancer
Dec 23, 2022 08:32AM Biostage (BSTG) Reports Publication Showing Rapid Esophageal Regeneration using the Biostage Esophageal Implant
Dec 23, 2022 08:30AM New Publication Demonstrates Rapid Esophageal Regeneration using the Biostage Esophageal Implant
Nov 14, 2022 04:22PM Biostage Reports Corporate Highlights and Third Quarter Financial Results
Oct 25, 2022 08:06AM Biostage (BSTG) Granted US Patent for Cellularized Patch-Based Scaffolds for Organ Repair
Oct 25, 2022 08:00AM Biostage Receives U.S. Patent for Cellularized Patch-Based Scaffolds for Organ Repair
Aug 4, 2022 04:05PM Biostage Reports Corporate Highlights and Second Quarter Financial Results
Jun 15, 2022 08:32AM Biostage (BSTG) Reports Publication of Mechanical Strength Data for Regenerated Esophageal Tissue in Journal of Biomechanics
Jun 15, 2022 08:30AM Biostage Announces Publication of Mechanical Strength Data for Regenerated Esophageal Tissue in Journal of Biomechanics
May 16, 2022 04:05PM Biostage Reports Q1 2022 Financial Results and Corporate Highlights
Apr 11, 2022 08:30AM Biostage Further Strengthens IP Portfolio with Additional Patent for Regeneration and Repair of the Bronchus
Apr 1, 2022 07:32AM Biostage Reports Fourth Quarter and Fiscal Year 2021 Financial Results
Nov 15, 2021 04:05PM Biostage Reports Q3 2021 Financial Results
Sep 8, 2021 08:00AM Biostage™ Appoints Jerry He to Board of Directors and Completes Private Placement of $2.6 Million to Continue Its Clinical Transition
Aug 13, 2021 04:05PM Biostage Reports Q2 2021 Financial Results
May 24, 2021 04:05PM Biostage Reports Q1 2021 Financial Results
Apr 13, 2021 04:05PM Biostage Reports 2020 Financial Results and Appointment of Interim Vice President of Finance
Jan 25, 2021 08:00AM Biostage Strengthens Board of Directors with Appointment of Herman Sanchez
Nov 13, 2020 04:05PM Biostage Reports Third Quarter 2020 Financial Results
Aug 13, 2020 04:05PM Biostage Reports Second Quarter 2020 Financial Results
May 14, 2020 04:05PM Biostage Reports First Quarter 2020 Financial Results
Mar 27, 2020 04:05PM Biostage Reports 2019 Financial Results
Mar 20, 2020 07:00AM Biostage Announces IND Approval from FDA for its Lead Product Candidate Cellspan™ Esophageal Implant
Feb 20, 2020 04:01PM Biostage Submitted Official Response to FDA for Investigational New Drug Application for its Lead Product Candidate Cellspan™ Esophageal Implant
Jan 2, 2020 05:00PM Biostage Provides Update on FDA Investigational New Drug Application for its Lead Product Candidate Cellspan™ Esophageal Implant
Dec 3, 2019 04:05PM Biostage Receives Response from the FDA for Investigational New Drug Application for its Lead Product Candidate Cellspan™ Esophageal Implant
Nov 12, 2019 07:00AM Biostage Reports Third Quarter 2019 Financial Results
Nov 6, 2019 05:30PM ­­Biostage to Host Conference Call to Discuss Third Quarter 2019 Financial Results and Business Update
Oct 30, 2019 08:00AM Biostage Submits Investigational New Drug (IND) Application for Lead Product Candidate Cellspan™ Esophageal Implant for Treatment of Esophageal Conditions
Aug 13, 2019 07:00AM Biostage Reports Second Quarter 2019 Financial Results
Aug 7, 2019 04:30PM Biostage to Host Conference Call to Discuss Second Quarter 2019 Financial Results and Business Update
May 14, 2019 07:00AM Biostage Reports First Quarter 2019 Financial Results
May 8, 2019 05:00PM Biostage to Host Conference Call to Discuss First Quarter 2019 Financial Results and Business Update
Mar 28, 2019 07:00AM Biostage Reports 2018 Financial Results
Mar 21, 2019 04:15PM Biostage to Host Conference Call to Discuss 2018 Financial Results and Business Update
Jan 28, 2019 08:00AM First-In-Human Case Using Biostage's Bioengineered Esophageal Implant is Presented at Major Surgical Meeting
Nov 8, 2018 08:00AM Mr. Matthew Dallas and Mr. Jeffrey Young Appointed to Biostage Board of Directors
Nov 8, 2018 07:00AM Biostage Reports 2018 Third Quarter Financial Results
Nov 7, 2018 12:10AM Ms. Ting Li Appointed to Biostage Board of Directors
Nov 6, 2018 07:20AM Biostage (BSTG) Secures $1.1M Phase Phase II NIH SBIR Fast-Track Grant to Develop Cellspan Esophageal Implant
Nov 6, 2018 07:00AM Biostage awarded $1.1 million Phase II NIH SBIR Fast-Track grant to develop Cellspan™ Esophageal Implant (CEI) as a novel treatment for pediatric esophageal atresia
Nov 2, 2018 04:30PM Biostage to Host Conference Call to Discuss Third Quarter 2018 Financial Results and Operations
Aug 14, 2018 07:00AM Biostage Reports 2018 Second Quarter Financial Results
Aug 9, 2018 02:29PM Biostage to Host Conference Call to Discuss Second Quarter 2018 Financial Results and Operations
May 31, 2018 05:00PM Biostage Closes $3.6 Million Private Placement at a price of $3.60 per share
View Older Stories